2. Others NF-κB Anti-infection Metabolic Enzyme/Protease
  3. NF-κB Environmental Pollutants Bacterial Endogenous Metabolite
  4. Myristic acid

Myristic acid is an orally active saturated 14-carbon fatty acid found in most animal and plant fats, especially milk fat coconut oil, palm oil and nutmeg oil. Myristic acid exerts anti-inflammatory activity through the NF-κB pathway. Myristic acid has antibacterial, anti-inflammatory and analgesic properties.

For research use only. We do not sell to patients.

CAS No. : 544-63-8

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
500 mg In-stock
1 g In-stock
5 g   Get quote  
10 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 7 publication(s) in Google Scholar

Other Forms of Myristic acid:

Myristic acid Related Antibodies

Top Publications Citing Use of Products

    Myristic acid purchased from MedChemExpress. Usage Cited in: Redox Biol. 2025 Feb 3:80:103528.  [Abstract]

    OVCAR8 and A2780 cells were cultured in fatty acid-free media supplemented with 50 μM AA (arachidonic acid), 50 μM OA (oleic acid), 50 μM EPA (eicosapentaenoic acid), 50 μM PA (Palmitic acid), and 50 μM MA (myristic acid) with the treatment of 10 μM niraparib for 72 h, and the cell viability was determined.

    Myristic acid purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2025 Aug 19;6(8):102260.  [Abstract]

    Myristic acid (20 μg/mL; 4-6 h). PA inhibited the amidolysis of APC on the chromogen substrate S-2366, whereas POA, MA, OA, and EA had no effect on APC activity (n = 3).

    Myristic acid purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2025 Aug 19;6(8):102260.  [Abstract]

    Intravenous administration of PA promoted venous thrombosis in the model of venous thrombosis induced by ligating the inferior vena cava, whereas POA, MA, OA, and EA had no effect on venous thrombosis. The inferior vena cava was removed 24 h later for H&E staining to observe thrombosis (left), and the weight of venous thrombus in each group was counted (right) (n = 6).

    Myristic acid purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2025 Aug 19;6(8):102260.  [Abstract]

    Intravenous administration of PA promoted arterial thrombosis in the model of carotid artery thrombosis induced by 10% FeCl₃, whereas POA, MA, OA, and EA had no effect on arterial thrombosis. Representative images of carotid artery blood flow (top) by laser speckle perfusion imaging were shown, and the region of interest (orange rectangle) was placed in the carotid artery to quantify blood flow change. Blood flow change in the region of interest was shown (bottom) by using perfusion units (n = 6).

    Myristic acid purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2025 Aug 19;6(8):102260.  [Abstract]

    PA promoted thrombin generation as evaluated by thrombin generation assays (TGA) in human plasma, including the thrombin generation curve.

    View All NF-κB Isoform Specific Products:

    View All Isoforms
    NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

    View All Endogenous Metabolite Isoform Specific Products:

    View All Isoforms
    Human Endogenous Metabolite Microbial Metabolite

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Myristic acid is an orally active saturated 14-carbon fatty acid found in most animal and plant fats, especially milk fat coconut oil, palm oil and nutmeg oil. Myristic acid exerts anti-inflammatory activity through the NF-κB pathway. Myristic acid has antibacterial, anti-inflammatory and analgesic properties[1][2][3][4].

    IC50 & Target

    Human Endogenous Metabolite

     

    Cellular Effect
    Cell Line Type Value Description References
    A549 IC50
    2 x 102 μM
    Compound: MA
    Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
    Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
    		[PMID: 37462318]
    CHO EC50
    11.4 μM
    Compound: 20
    Agonist activity at recombinant human GPR84 expressed in CHO cell membranes co-expressing beta-arrestin2 assessed as inhibition of forskolin-stimulated [3H]cAMP accumulation preincubated for 5 mins followed by forskolin stimulation and measured after 15 mins by radioactive assay
    Agonist activity at recombinant human GPR84 expressed in CHO cell membranes co-expressing beta-arrestin2 assessed as inhibition of forskolin-stimulated [3H]cAMP accumulation preincubated for 5 mins followed by forskolin stimulation and measured after 15 mins by radioactive assay
    		[PMID: 31721581]
    CHO EC50
    7.01 μM
    Compound: 20
    Agonist activity at recombinant human GPR84 expressed in CHO cell membranes co-expressing beta-arrestin2 assessed as beta-arrestin 2 recruitment measured after 90 mins by beta-galactosidase based PathHunter assay
    Agonist activity at recombinant human GPR84 expressed in CHO cell membranes co-expressing beta-arrestin2 assessed as beta-arrestin 2 recruitment measured after 90 mins by beta-galactosidase based PathHunter assay
    		[PMID: 31721581]
    Caco-2 IC50
    > 1 x 103 μM
    Compound: MA
    Cytotoxicity against human Caco-2 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
    Cytotoxicity against human Caco-2 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
    		[PMID: 37462318]
    Huh-7 CC50
    > 50 μM
    Compound: Myristic acid
    Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability measured after 24 hrs by CellTiter-Glo analysis
    Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability measured after 24 hrs by CellTiter-Glo analysis
    		[PMID: 34583312]
    THP-1 IC50
    5 μM
    Compound: myristic acid
    Inhibition of TLR2 agonist Pam3Cys-Ser-(Lys)4-OH-mediated IL8 secretion in THP1 cells
    Inhibition of TLR2 agonist Pam3Cys-Ser-(Lys)4-OH-mediated IL8 secretion in THP1 cells
    		[PMID: 16509590]
    In Vitro

    Myristic acid (100, 150, 200 μM, 24 h) regulates the production of triglyceride in bovine mammary epithelial cells through ubiquitination pathway[1].
    Myristic acid (3-1000 μM, 10 min) can inhibit the activity of bacterial ABC transporter BmrA[2].
    Myristic acid (12.5-200 μg/mL, 24 h) exerts in vitro anti-inflammatory activity by increasing (58%) IL-10 production in LPS (HY-D1056)-stimulated macrophages[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Myristic acid Related Antibodies

    Western Blot Analysis[1]

    Cell Line: MAC-T
    Concentration: 100, 150, 200 μM
    Incubation Time: 24 h
    Result: Increased the level of protein ubiquitination.

    Cell Viability Assay[3]

    Cell Line: J774A.1 macrophages
    Concentration: 12.5, 25, 50, 100,200 μg/mL
    Incubation Time: 24 h
    Result: Showed non-cytotoxic effects in LPS-stimulated J774A.1 macrophages at 25 μg/mL.
    In Vivo

    Myristic acid (12.5-100 mg/kg, orally, Single dose) has good anti-inflammatory effect on ear edema induced by acute (ED50 = 62 mg/kg) and chronic (ED50 = 77 mg/kg) mice[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: TPA-induced ear edema in mice[3]
    Dosage: 12.5, 25, 50, 100 mg/kg
    Administration: p.o.
    Result: Decreased ear edema inflammation in the acute and chronic TPA assays with IC50 values of 62 and 77 mg/kg, respectively in a dose-dependent manner.
    Attenuated the acetic acid-induced abdominal contortions with ED50 values of 32 mg/kg.
    Molecular Weight

    228.37

    Formula

    C14H28O2
    CAS No.
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    CCCCCCCCCCCCCC(O)=O
    Structure Classification
    Initial Source
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage

    Store at room temperature 3 years

    In solvent -80°C 2 years
    -20°C 1 year
    Solvent & Solubility
    In Vitro: 

    DMSO : 200 mg/mL (875.77 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Ethanol : 100 mg/mL (437.89 mM; Need ultrasonic)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 4.3789 mL 21.8943 mL 43.7886 mL
    5 mM 0.8758 mL 4.3789 mL 8.7577 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 5 mg/mL (21.89 mM); Clear solution

      This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% Corn Oil

      Solubility: ≥ 5 mg/mL (21.89 mM); Clear solution

      This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL Corn oil, and mix evenly.

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  Cremophor EL

      Solubility: 40 mg/mL (175.15 mM); Clear solution; Need ultrasonic

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.88%

    SDS (393 KB)

    COA (238 KB) HNMR (129 KB) RP-HPLC (244 KB)

    Handling Instructions (2659 KB)
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    Ethanol / DMSO 1 mM 4.3789 mL 21.8943 mL 43.7886 mL 109.4715 mL
    5 mM 0.8758 mL 4.3789 mL 8.7577 mL 21.8943 mL
    10 mM 0.4379 mL 2.1894 mL 4.3789 mL 10.9471 mL
    15 mM 0.2919 mL 1.4596 mL 2.9192 mL 7.2981 mL
    20 mM 0.2189 mL 1.0947 mL 2.1894 mL 5.4736 mL
    25 mM 0.1752 mL 0.8758 mL 1.7515 mL 4.3789 mL
    30 mM 0.1460 mL 0.7298 mL 1.4596 mL 3.6490 mL
    40 mM 0.1095 mL 0.5474 mL 1.0947 mL 2.7368 mL
    50 mM 0.0876 mL 0.4379 mL 0.8758 mL 2.1894 mL
    60 mM 0.0730 mL 0.3649 mL 0.7298 mL 1.8245 mL
    80 mM 0.0547 mL 0.2737 mL 0.5474 mL 1.3684 mL
    100 mM 0.0438 mL 0.2189 mL 0.4379 mL 1.0947 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Myristic acid Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Myristic acid544-63-8NF-κBEnvironmental PollutantsBacterialEndogenous MetaboliteNuclear factor-κBNuclear factor-kappaBEnvironmental ContaminantsAnti-inflammatoryAntibacterialMAC-TJ774A.1 macrophagesEar edemaInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Myristic acid
    Cat. No.:
    HY-N2041
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB) Italian - IT (393 KB) Korean - KR (393 KB) Portuguese - PT (393 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.